Immatics N.V. (IMTX)
Market Cap | 1.27B |
Revenue (ttm) | 80.95M |
Net Income (ttm) | -87.28M |
Shares Out | 103.05M |
EPS (ttm) | -1.07 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 297,458 |
Open | 12.61 |
Previous Close | 12.39 |
Day's Range | 12.26 - 12.61 |
52-Week Range | 7.15 - 13.77 |
Beta | 0.75 |
Analysts | Strong Buy |
Price Target | 16.00 (+30.08%) |
Earnings Date | Aug 15, 2024 |
About IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203... [Read more]
Analyst Forecast
According to 2 analysts, the average rating for IMTX stock is "Strong Buy." The 12-month stock price forecast is $16.0, which is an increase of 30.08% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/l/v/press10-2428950.jpg)
Immatics Announces First Quarter 2024 Financial Results and Business Update
Company Provides Clinical Data Update from Ongoing Phase 1 Clinical Trial with ACTengine® IMA203 TCR-T Targeting PRAME
![](https://cdn.snapi.dev/images/v1/x/d/press17-2334837.jpg)
Immatics Announces Full Year 2023 Financial Results and Corporate Update
Houston, Texas and Tuebingen, Germany, March 21, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...
![](https://cdn.snapi.dev/images/v1/j/y/press16-2233698.jpg)
Immatics Announces Pricing of $175 Million Public Offering
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...
![](https://cdn.snapi.dev/images/v1/b/f/press2-2233350.jpg)
Immatics Announces Proposed Public Offering
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...
![](https://cdn.snapi.dev/images/v1/b/g/press7-2156363.jpg)
Immatics Announces Third Quarter 2023 Financial Results and Business Update
Tuebingen, Germany and Houston, TX, November 14, 2023 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...
![](https://cdn.snapi.dev/images/v1/4/t/press9-2146380.jpg)
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
Company to host conference call and webcast today, November 8, at 8:30 am EST/2:30 pm CET
![](https://cdn.snapi.dev/images/v1/l/d/press10-2116814.jpg)
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
RMAT designation granted by FDA CBER for IMA203 cell therapy in multiple PRAME-expressing tumors including cutaneous and uveal melanoma, ovarian cancer and other cancer types Regulatory activities und...
![](https://cdn.snapi.dev/images/v1/j/a/press13-2059011.jpg)
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors
Appointment effective as of September 14, 2023; Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel , Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX),...
![](https://cdn.snapi.dev/images/v1/v/s/biotech18-2057507.jpg)
Immatics shares rise on Moderna cancer collaboration
Immatics NV shares IMTX, -2.87% gained more than 6% premarket on Monday after the company announced a collaboration with Moderna Inc. MRNA, -0.66% to research and develop new cancer therapies. The par...
![](https://cdn.snapi.dev/images/v1/o/j/3vlhfofhnvninlqqjjp6v3kh44-2057226.jpg)
Moderna, Immatics to work jointly on cancer vaccines
Vaccine maker Moderna said on Monday it had struck a deal with Immatics for developing cancer vaccines and therapies and would pay the drug developer $120 million in cash and additional milestone paym...
![](https://cdn.snapi.dev/images/v1/e/e/press7-2057109.jpg)
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Cambridge, Massachusetts and Tuebingen , Germany , September 11 , 2023 – Moderna, Inc. (NASDAQ: MRNA, “Moderna”) and Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical compan...
![](https://cdn.snapi.dev/images/v1/h/4/press20-2057125.jpg)
Moderna & Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules Companies to leverage Immatics' XPRESIDENT® target discovery platform and Moderna's ...
![](https://cdn.snapi.dev/images/v1/r/j/press17-2026647.jpg)
Immatics Announces Second Quarter 2023 Financial Results and Business Update
Tuebingen, Germany and Houston , TX, August 17 , 2023 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...
![](https://cdn.snapi.dev/images/v1/r/s/press4-2016718.jpg)
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors
Tuebingen, Germany and Houston, Texas , August 10 , 202 3 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redir...
![](https://cdn.snapi.dev/images/v1/g/c/urlhttps3a2f2fgfoolcdncom2feditorial2fimages2f6012512fa-researcher-studying-a-sample-in-a-petri-dishjpgw700opresize-1984025.jpg)
Immatics shares jump after investment from Bristol Myers Squibb
Shares of Immatics N.V. IMTX, +0.08% gained more than 8% premarket on Monday after the clinical-stage biopharma company said it had received a $35 million equity investment from Bristol Myers Squibb C...
![](https://cdn.snapi.dev/images/v1/m/g/press12-1983890.jpg)
Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb
Tuebingen , Germany and Houston , TX , Ju ly 24 , 202 3 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirec...
![](https://cdn.snapi.dev/images/v1/j/4/press1-1891792.jpg)
Immatics Announces First Quarter 2023 Financial Results and Business Update
Tuebingen , Germany and Houston, TX , May 16 , 20 2 3 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecti...
![](https://cdn.snapi.dev/images/v1/k/3/press10-1864978.jpg)
Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME
Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST
![](https://cdn.snapi.dev/images/v1/u/r/press18-1862668.jpg)
Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration
Tuebingen, Germany & Houston, May 1, 2023 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer im...
![](https://cdn.snapi.dev/images/v1/u/a/press16-1805556.jpg)
Immatics Announces Full Year 2022 Financial Results and Corporate Update
Tuebingen , Germany and Houston, TX , March 2 1 , 20 2 3 – Immatics N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redire...
![](https://cdn.snapi.dev/images/v1/l/g/press13-1641382.jpg)
Immatics Announces Third Quarter 2022 Financial Results and Business Update
Tuebingen , Germany and Houston, Texas , November 1 7 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-re...
![](https://cdn.snapi.dev/images/v1/i/w/press1-1575355.jpg)
Immatics Announces $110 Million Underwritten Offering of Ordinary Shares
H ouston, Texas and Tuebingen , Germany , October 10, 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redi...
![](https://cdn.snapi.dev/images/v1/s/1/press19-1575353.jpg)
Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME
Company to host conf e rence call today, October 10 , at 8:30 am E D T / 2:30 pm CEST
![](https://cdn.snapi.dev/images/v1/w/i/press13-1539051.jpg)
Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022
TCER® IMA402 is a next-generation, half-life extended TCR Bispecific targeting an HLA-A*02:01-presented peptide derived from PRAME. In preclinical studies, IMA402 demonstrated enhanced anti-tumor acti...
![](https://cdn.snapi.dev/images/v1/v/t/press17-1515223.jpg)
Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME
H ouston, Texas and Tuebingen , Germany , August 23 , 2022 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redi...